Santen Pharmaceutical Co., Ltd.
https://www.santen.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Santen Pharmaceutical Co., Ltd.
Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Coronavirus Update: Will Moderna Really Demand Premium Price For COVID Vaccine?
There are reports that the US biotech is considering pricing its as-yet-unapproved mRNA-1273 at $25-30 a dose, a price which would double as both a prime and boost dose would be administered.
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Eyevance Pharmaceuticals LLC.
- Novagali Pharma SA
- Santen Inc.
- Chongqing Santen Kerui Pharmaceutical Co., Ltd
- InnFocus Inc,